Abstract
The present study deciphers the formulation of Quercetin (QRN) loaded nanoemulsion (NE). The nanoemulsion was prepared by using Labrafil M 1944CS as oil phase, Labrafac PG as surfactant, Transcutol P as co-surfactant. The composition was optimized by applying three-level central composite design. The optimized formulation showed droplet size of 41.22 +/- 6.38 nm, zeta potential was - 38.52 +/- 5.16 mV and drug loading were 87.67 +/- 3.32%. The results of dissolution, permeability and oral bioavailability showed about 11.70 folds, 3.44 folds and 28.29 folds, respectively in case of NE-QRN as compared to its naive form. The results of particle size, zeta potential, and drug loading showed a non-significant change in the response of fresh and aged NE, which indicated that the formulation was stable. The outcomes of successful development of NE-QRN with enhanced bioavailability profile indicated towards possibility to explore this formulation for pharmacodynamic assessment of oxidative stress based metabolic diseases. In vitro results on H9C2 cell line indicated lower cellular proliferation rate after treatment with NE-QRN with decreased cytoplasmic expression of Ace protein. The NE was stable at accelerated stability conditions. Overall results indicated successful development of NE-QRN.